Contributors |
|
iv | |
Preface |
|
vii | |
Acknowledgments |
|
viii | |
Introduction |
|
xxi | |
|
1 Hypothalamic-Pituitary Disease |
|
|
1 | (42) |
|
|
|
|
|
|
Introduction of the Hypothalamic-Pituitary Axis |
|
|
1 | (1) |
|
|
1 | (4) |
|
Epidemiology and Pathogenesis |
|
|
1 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
3 | (1) |
|
Postoperative Complications |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
5 | (9) |
|
|
5 | (1) |
|
|
6 | (1) |
|
Secondary Adrenal Insufficiency |
|
|
6 | (2) |
|
Central or Secondary Hypothyroidism |
|
|
8 | (1) |
|
|
8 | (1) |
|
Growth Hormone Deficiency |
|
|
9 | (2) |
|
|
11 | (1) |
|
|
11 | (1) |
|
|
11 | (1) |
|
|
11 | (1) |
|
|
11 | (1) |
|
Nonfunctional Adenomas and Gonadotropin-Producing Adenomas |
|
|
12 | (1) |
|
|
13 | (1) |
|
|
13 | (1) |
|
Imaging of the Hypothalamic-Pituitary System |
|
|
14 | (2) |
|
Radiologic Imaging Techniques |
|
|
14 | (2) |
|
|
16 | (1) |
|
Disorders of the Prolactin System |
|
|
16 | (3) |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
17 | (1) |
|
|
18 | (1) |
|
Pregnancy and Hyperprolactinemia |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
20 | (1) |
|
Pathophysiology and Clinical Presentation |
|
|
20 | (1) |
|
|
20 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
21 | (1) |
|
|
22 | (1) |
|
|
22 | (1) |
|
Growth Hormone Receptor Antagonist |
|
|
22 | (1) |
|
|
22 | (2) |
|
|
22 | (1) |
|
|
23 | (1) |
|
Central Diabetes Insipidus |
|
|
23 | (1) |
|
Nephrogenic Diabetes Insipidus |
|
|
23 | (1) |
|
|
23 | (1) |
|
|
23 | (1) |
|
|
24 | (1) |
|
Central Diabetes Insipidus |
|
|
24 | (1) |
|
Nephrogenic Diabetes Insipidus |
|
|
24 | (1) |
|
|
24 | (3) |
|
Etiology and Pathogenesis |
|
|
24 | (1) |
|
|
25 | (1) |
|
|
25 | (1) |
|
High-Dose Dexamethasone Suppression Test |
|
|
25 | (1) |
|
Bilateral Inferior Petrosal Sinus Sampling |
|
|
25 | (1) |
|
|
26 | (1) |
|
Syndrome of Inappropriate Antidiuretic Hormone Secretion |
|
|
27 | (3) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
29 | (1) |
|
|
29 | (1) |
|
Vasopressin Receptor Antagonists |
|
|
29 | (1) |
|
|
30 | (13) |
|
|
43 | (38) |
|
|
|
Evaluation of Thyroid Function |
|
|
43 | (2) |
|
|
43 | (1) |
|
|
44 | (1) |
|
Total Thyroxine and Triiodothyronine |
|
|
44 | (1) |
|
|
44 | (1) |
|
|
45 | (1) |
|
|
45 | (1) |
|
|
45 | (1) |
|
|
45 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
|
46 | (1) |
|
18F-Fluorodeoxyglucose Positron Emission Tomography |
|
|
46 | (1) |
|
|
46 | (4) |
|
|
46 | (1) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
48 | (1) |
|
Antithyroid Drugs plus LT4 |
|
|
48 | (2) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
|
50 | (1) |
|
Epidemiology and Pathophysiology |
|
|
51 | (1) |
|
|
51 | (1) |
|
|
51 | (1) |
|
|
51 | (1) |
|
LT4 plus Liothyronine (T3) |
|
|
51 | (1) |
|
|
51 | (2) |
|
|
51 | (1) |
|
|
52 | (1) |
|
|
52 | (1) |
|
|
52 | (1) |
|
|
52 | (1) |
|
Suppressive Therapy with Levothyroxine |
|
|
52 | (1) |
|
|
53 | (1) |
|
Percutaneous Ethanol Injection |
|
|
53 | (1) |
|
Laser Thermal Ablation (2B) |
|
|
53 | (1) |
|
|
53 | (3) |
|
Definition and Classification |
|
|
53 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
Fine-Needle Aspiration Biopsy |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
54 | (1) |
|
|
55 | (1) |
|
|
55 | (1) |
|
Radioiodine Remnant Ablation |
|
|
55 | (1) |
|
Thyroid Hormone Suppression of TSH |
|
|
56 | (1) |
|
Tyrosine Kinase Inhibitors |
|
|
56 | (1) |
|
|
56 | (1) |
|
|
56 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
|
57 | (1) |
|
Triiodothyronine Replacement |
|
|
57 | (1) |
|
|
57 | (24) |
|
|
81 | (41) |
|
|
|
Evaluation of Adrenal Function |
|
|
81 | (2) |
|
Evaluation of Glucocorticoid Function |
|
|
81 | (1) |
|
|
81 | (1) |
|
Adrenocorticotropic Hormone |
|
|
82 | (1) |
|
|
82 | (1) |
|
Evaluation of Mineralocorticoid Function |
|
|
82 | (1) |
|
Evaluation of Adrenal Medulla |
|
|
82 | (1) |
|
Evaluation of Adrenal Androgen Production and Congenital Adrenal Hyperplasia in Adults |
|
|
83 | (1) |
|
|
83 | (3) |
|
Computed Tomography Scanning |
|
|
83 | (1) |
|
Magnetic Resonance Imaging |
|
|
84 | (1) |
|
Adrenal Cortical Scintigraphy |
|
|
85 | (1) |
|
Adrenal Medullary Scintigraphy |
|
|
85 | (1) |
|
Positron Emission Tomography |
|
|
86 | (1) |
|
|
86 | (1) |
|
Primary Hyperaldosteronism |
|
|
86 | (4) |
|
|
86 | (1) |
|
|
87 | (1) |
|
|
87 | (1) |
|
|
87 | (2) |
|
|
89 | (1) |
|
|
90 | (3) |
|
Etiology and Pathogenesis |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (1) |
|
|
92 | (1) |
|
|
93 | (3) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
93 | (1) |
|
|
94 | (1) |
|
|
95 | (1) |
|
|
96 | (4) |
|
|
96 | (1) |
|
Etiology and Epidemiology |
|
|
96 | (1) |
|
|
96 | (1) |
|
|
96 | (1) |
|
|
96 | (2) |
|
|
98 | (1) |
|
|
99 | (1) |
|
|
99 | (1) |
|
|
100 | (4) |
|
|
100 | (1) |
|
|
100 | (1) |
|
|
101 | (1) |
|
|
102 | (1) |
|
|
103 | (1) |
|
|
104 | (18) |
|
4 Metabolic Bone Disorders |
|
|
|
|
|
|
Evaluation of Metabolic Bone Disorders |
|
|
122 | (2) |
|
Serum Calcium, Phosphate, and Magnesium |
|
|
122 | (1) |
|
Intact Parathyroid Hormone |
|
|
122 | (1) |
|
|
122 | (1) |
|
Parathyroid Hormone-Related Protein |
|
|
123 | (1) |
|
|
123 | (1) |
|
Urinary Calcium Excretion |
|
|
123 | (1) |
|
Biochemical Markers of Bone Turnover |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
124 | (1) |
|
|
124 | (3) |
|
|
125 | (1) |
|
|
126 | (1) |
|
Quantitative Computed Tomography |
|
|
126 | (1) |
|
Micro-Computed Tomography |
|
|
126 | (1) |
|
|
126 | (1) |
|
Magnetic Resonance Imaging |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
127 | (19) |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
130 | (4) |
|
|
134 | (1) |
|
|
134 | (1) |
|
|
134 | (1) |
|
|
134 | (1) |
|
Atypical Femoral Fractures |
|
|
134 | (3) |
|
|
137 | (1) |
|
|
137 | (1) |
|
|
138 | (1) |
|
Hormone Replacement Therapy |
|
|
138 | (1) |
|
|
138 | (1) |
|
|
138 | (3) |
|
|
141 | (3) |
|
|
144 | (1) |
|
|
144 | (2) |
|
|
146 | (1) |
|
|
146 | (3) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (1) |
|
|
147 | (2) |
|
|
149 | (1) |
|
|
149 | (1) |
|
Primary Hyperparathyroidism |
|
|
149 | (4) |
|
|
149 | (1) |
|
|
149 | (1) |
|
|
150 | (1) |
|
|
150 | (1) |
|
|
151 | (1) |
|
|
151 | (1) |
|
|
152 | (1) |
|
|
153 | (1) |
|
|
153 | (1) |
|
|
153 | (1) |
|
|
153 | (1) |
|
|
154 | (1) |
|
|
154 | (1) |
|
|
154 | (4) |
|
|
154 | (1) |
|
|
155 | (1) |
|
Address the Primary Cause |
|
|
155 | (1) |
|
Decrease Intestinal Absorption |
|
|
155 | (1) |
|
Increase Urinary Calcium Excretion |
|
|
155 | (1) |
|
|
156 | (1) |
|
|
157 | (1) |
|
Hypercalcemie Emergencies |
|
|
157 | (1) |
|
|
157 | (1) |
|
|
158 | (2) |
|
|
158 | (1) |
|
|
158 | (1) |
|
|
158 | (1) |
|
|
159 | (1) |
|
|
159 | (1) |
|
|
160 | (1) |
|
|
160 | (1) |
|
|
160 | (2) |
|
Vitamin D-Dependent Rickets (Type 1 and Type 2) |
|
|
161 | (1) |
|
|
161 | (1) |
|
|
161 | (1) |
|
|
162 | (1) |
|
Drug-Induced Osteomalacia |
|
|
162 | (1) |
|
|
162 | (2) |
|
|
162 | (1) |
|
|
162 | (1) |
|
|
163 | (1) |
|
|
163 | (1) |
|
|
163 | (1) |
|
|
164 | (1) |
|
|
164 | (1) |
|
|
164 | (1) |
|
|
164 | (26) |
|
|
190 | (39) |
|
|
|
|
190 | (4) |
|
|
190 | (1) |
|
|
190 | (1) |
|
|
190 | (1) |
|
|
190 | (1) |
|
|
191 | (1) |
|
|
192 | (1) |
|
|
193 | (1) |
|
|
193 | (1) |
|
Hyperandrogenism and PCOS |
|
|
194 | (3) |
|
|
194 | (3) |
|
|
197 | (1) |
|
PCOS and Insulin Resistance (Metabolic Syndrome) |
|
|
197 | (3) |
|
|
198 | (1) |
|
|
198 | (2) |
|
Insulin-Sensitizing Drugs |
|
|
200 | (1) |
|
|
200 | (2) |
|
|
200 | (1) |
|
|
200 | (1) |
|
|
200 | (1) |
|
|
201 | (1) |
|
|
202 | (4) |
|
|
202 | (1) |
|
|
203 | (1) |
|
Congenital Male Hypogonadism |
|
|
203 | (1) |
|
Acquired Male Hypogonadism |
|
|
203 | (2) |
|
|
205 | (1) |
|
|
206 | (1) |
|
|
207 | (2) |
|
|
207 | (1) |
|
|
207 | (1) |
|
|
207 | (1) |
|
|
207 | (1) |
|
|
208 | (1) |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
210 | (19) |
|
|
229 | (50) |
|
|
|
|
229 | (6) |
|
|
229 | (1) |
|
|
229 | (1) |
|
|
229 | (1) |
|
Major Histocompatibility Complex Genes |
|
|
229 | (1) |
|
Insulin-Dependent Diabetes Mellitus Genes |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
230 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
231 | (1) |
|
|
232 | (1) |
|
|
232 | (1) |
|
|
232 | (2) |
|
|
234 | (1) |
|
|
234 | (1) |
|
|
234 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
235 | (9) |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
236 | (1) |
|
Pathophysiology of Type 2 Diabetes Mellitus |
|
|
236 | (1) |
|
|
236 | (1) |
|
|
236 | (1) |
|
|
237 | (1) |
|
|
237 | (1) |
|
|
237 | (1) |
|
|
238 | (1) |
|
Weight Reduction and Dietary Restrictions |
|
|
238 | (1) |
|
|
238 | (1) |
|
|
238 | (3) |
|
Noninsulin Injectable Therapies |
|
|
241 | (2) |
|
|
243 | (1) |
|
|
244 | (1) |
|
|
244 | (3) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
245 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
248 | (3) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
249 | (1) |
|
|
250 | (1) |
|
|
250 | (1) |
|
|
250 | (1) |
|
|
251 | (8) |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
251 | (2) |
|
|
253 | (1) |
|
|
253 | (1) |
|
|
253 | (1) |
|
|
254 | (1) |
|
|
254 | (1) |
|
|
254 | (1) |
|
|
255 | (1) |
|
|
255 | (1) |
|
|
255 | (1) |
|
|
255 | (1) |
|
|
256 | (1) |
|
|
256 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
257 | (1) |
|
|
258 | (1) |
|
Intensive Glycemic Management |
|
|
259 | (3) |
|
|
259 | (1) |
|
|
259 | (1) |
|
|
259 | (1) |
|
|
259 | (1) |
|
|
260 | (1) |
|
|
260 | (1) |
|
|
260 | (1) |
|
|
260 | (2) |
|
|
262 | (17) |
|
|
279 | (21) |
|
|
|
|
279 | (2) |
|
Low-Density Lipoprotein Cholesterol |
|
|
281 | (7) |
|
|
281 | (1) |
|
Primary Prevention Trials |
|
|
281 | (3) |
|
Secondary Prevention Trials |
|
|
284 | (1) |
|
|
284 | (1) |
|
|
285 | (1) |
|
|
285 | (1) |
|
Statins (3-Hydroxy-3-Methylglutaryl Coenzyme A Reduetase Inhibitors) |
|
|
285 | (1) |
|
Statin Therapy in High-Risk Populations |
|
|
285 | (2) |
|
|
287 | (1) |
|
Bile Acid Sequestrants (Resins) |
|
|
288 | (1) |
|
Nicotinic Acid and Fibric Acids |
|
|
288 | (1) |
|
|
288 | (1) |
|
Nonpharmacologic Strategies |
|
|
288 | (1) |
|
High-Density Lipoprotein Cholesterol and Triglycerides |
|
|
288 | (3) |
|
|
289 | (1) |
|
Therapeutic Lifestyle Changes |
|
|
289 | (1) |
|
|
289 | (1) |
|
|
289 | (1) |
|
|
290 | (1) |
|
|
290 | (1) |
|
New Treatment Options for Increasing HDL |
|
|
290 | (1) |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
291 | (1) |
|
|
292 | (8) |
|
|
300 | (22) |
|
|
|
|
300 | (1) |
|
|
301 | (1) |
|
|
301 | (1) |
|
|
302 | (1) |
|
|
302 | (5) |
|
Therapeutic Lifestyle Changes |
|
|
303 | (1) |
|
|
303 | (1) |
|
Healthy Eating and Nutrition |
|
|
304 | (2) |
|
|
306 | (1) |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
308 | (1) |
|
|
308 | (1) |
|
|
309 | (13) |
|
9 Multiple Endocrine Neoplasia |
|
|
322 | (26) |
|
|
|
|
324 | (5) |
|
|
324 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
|
326 | (1) |
|
Insulin-Secreting and Other Tumor Types |
|
|
327 | (1) |
|
|
327 | (1) |
|
|
327 | (1) |
|
|
327 | (1) |
|
|
327 | (1) |
|
|
328 | (1) |
|
|
328 | (1) |
|
|
329 | (1) |
|
|
329 | (6) |
|
|
329 | (1) |
|
Medullary Thyroid Carcinoma |
|
|
330 | (1) |
|
|
330 | (1) |
|
|
330 | (3) |
|
|
333 | (1) |
|
|
333 | (1) |
|
|
334 | (1) |
|
|
335 | (1) |
|
|
335 | (1) |
|
Should Patients with Thyroid Nodules be Screened for MTC? |
|
|
335 | (1) |
|
|
336 | (12) |
|
|
348 | (7) |
|
|
|
|
|
348 | (1) |
|
|
348 | (1) |
|
|
349 | (1) |
|
|
349 | (1) |
|
|
350 | (1) |
|
|
350 | (1) |
|
|
351 | (1) |
|
|
352 | (3) |
|
11 Paraneoplastic Endocrine Syndromes |
|
|
355 | (17) |
|
|
Hypercalcemia of Malignancy |
|
|
355 | (5) |
|
|
355 | (1) |
|
|
356 | (1) |
|
|
357 | (1) |
|
|
357 | (1) |
|
|
358 | (1) |
|
|
358 | (1) |
|
|
359 | (1) |
|
Antiresorptive Agents (Bisphosphonates and Denosumab) for Treatment of Bone Metastases |
|
|
359 | (1) |
|
|
360 | (1) |
|
Tumor-Induced Osteomalacia |
|
|
360 | (1) |
|
Ectopic Adrenocorticotropic Hormone Syndrome |
|
|
361 | (2) |
|
Non-Islet Cell Tumor-Induced Hypoglycemia |
|
|
363 | (1) |
|
|
363 | (1) |
|
|
364 | (1) |
|
|
364 | (8) |
|
|
372 | (21) |
|
|
|
372 | (5) |
|
|
377 | (1) |
|
|
378 | (1) |
|
|
379 | (1) |
|
|
379 | (5) |
|
|
379 | (1) |
|
Information about Genetic Disorders |
|
|
380 | (1) |
|
|
380 | (1) |
|
|
380 | (1) |
|
|
381 | (1) |
|
Laboratories Performing Genetic Tests |
|
|
381 | (1) |
|
Practical Limitations of Genetic Testing |
|
|
382 | (2) |
|
|
384 | (1) |
|
|
384 | (1) |
|
|
384 | (9) |
Index |
|
393 | |